These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27603945)

  • 1. [Therapy of Metastatic Non-small Cell Lung Cancer].
    Reinmuth N; Gröschel A; Schumann C; Sebastian M; Wiewrodt R; Reck M
    Pneumologie; 2016 Sep; 70(9):567-78. PubMed ID: 27603945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer].
    Reinmuth N; Gröschel A; Schumann C; Sebastian M; Wiewrodt R; Reck M
    Pneumologie; 2018 Feb; 72(2):138-154. PubMed ID: 29270953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology.
    Manegold C
    Adv Med Sci; 2014 Sep; 59(2):308-13. PubMed ID: 25240504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
    García-Campelo R; Bernabé R; Cobo M; Corral J; Coves J; Dómine M; Nadal E; Rodriguez-Abreu D; Viñolas N; Massuti B
    Clin Transl Oncol; 2015 Dec; 17(12):1020-9. PubMed ID: 26691657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Peters S; Adjei AA; Gridelli C; Reck M; Kerr K; Felip E;
    Ann Oncol; 2012 Oct; 23 Suppl 7():vii56-64. PubMed ID: 22997455
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
    Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape.
    Riessk J
    Am J Manag Care; 2013 Dec; 19(19 Suppl):s390-7. PubMed ID: 24494720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-small cell lung cancer (NSCLC)].
    Yoshimori K
    Nihon Rinsho; 2002 May; 60 Suppl 5():294-7. PubMed ID: 12101676
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
    Duma N; Santana-Davila R; Molina JR
    Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
    Huber RM; Reck M; Thomas M
    Eur Respir J; 2013 Oct; 42(4):1119-33. PubMed ID: 23429914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
    Santarpia M; Altavilla G; Pitini V; Rosell R
    Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lung cancer : What has been confirmed in therapy?].
    Heigener DF; Reck M
    Internist (Berl); 2017 Dec; 58(12):1258-1263. PubMed ID: 29043377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic sentinel lymph node imaging.
    Kachala SS; Servais EL; Park BJ; Rusch VW; Adusumilli PS
    Semin Thorac Cardiovasc Surg; 2009; 21(4):327-38. PubMed ID: 20226346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
    Gardiner RE; Jahangeer S; Forde P; Ariffin AB; Bird B; Soden D; Hinchion J
    Cancer Metastasis Rev; 2015 Mar; 34(1):129-44. PubMed ID: 25726003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
    Shaw AT
    Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
    [No Abstract]   [Full Text] [Related]  

  • 19. [Personalized therapy in non-small cell lung cancer: from diagnosis to therapy].
    Moldvay J
    Orv Hetil; 2012 Jun; 153(23):909-16. PubMed ID: 22668592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-angiogenic strategy: therapy optimization of non-squamous non-small cell lung carcinoma].
    Reinmuth N; Reck M; Grohé C
    Pneumologie; 2014 Dec; 68(12):793-8. PubMed ID: 25489867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.